Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trial.
Lancet Gastroenterol HepatolJul 9, 2026 (epub)
John Burn, Gillian M Borthwick, Faye Elliott et al.
✦ AI-curated · Sources linked
In 30 seconds
The CaPP3 trial evaluated the efficacy of lower doses of aspirin (100 mg and 300 mg daily) compared to 600 mg daily in preventing Lynch syndrome cancers among 1866 participants with Lynch syndrome. This multicentre, randomised, double-blind trial found that both lower doses were non-inferior to the higher dose, with 216 cancers diagnosed across all groups during a median follow-up of 66.4 months.
Key findings
- 216 Lynch syndrome cancers were diagnosed among participants, with 84 in the 600 mg group.
- 730 participants (39.1%) stopped taking aspirin during the 2-year blinded phase.
- 937 participants (50.2%) completed 5 years of aspirin treatment.
Why it matters
This study provides evidence that lower doses of aspirin can effectively prevent cancers associated with Lynch syndrome, which may influence treatment strategies for patients at high risk of these malignancies.